Hologic, Inc. (NASDAQ:HOLX) Receives Average Rating of "Hold" from Brokerages

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) has been assigned a consensus rating of "Hold" from the seventeen ratings firms that are presently covering the firm, MarketBeat reports. Eleven investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $77.42.

A number of research firms have recently weighed in on HOLX. Royal Bank Of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Citigroup dropped their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Evercore ISI dropped their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.88% of the company's stock.

Institutional Trading of Hologic

Hedge funds and other institutional investors have recently modified their holdings of the stock. Venturi Wealth Management LLC grew its stake in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in shares of Hologic in the first quarter worth $34,000. Allworth Financial LP grew its stake in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Hologic in the first quarter worth $42,000. Institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

HOLX stock traded down $0.17 during mid-day trading on Friday, hitting $63.97. 3,239,812 shares of the company were exchanged, compared to its average volume of 2,330,435. The business has a 50 day simple moving average of $59.03 and a 200-day simple moving average of $64.64. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $14.26 billion, a PE ratio of 26.99, a price-to-earnings-growth ratio of 2.35 and a beta of 0.55. Hologic has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the business posted $1.03 earnings per share. On average, equities analysts forecast that Hologic will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.